ANXA1 in HNSCC Chemotherapy Resistance: Multi-Omics Analysis from TCGA and GEO

Ling Zheng published a bioinformatics analysis on March 18, 2026, investigating chemotherapy resistance in head and neck squamous cell carcinoma. The study integrates bulk and single-cell RNA sequencing data from the TCGA-HNSCC cohort and GEO datasets GSE6631, GSE65858, and GSE163872. It identifies ANXA1 as a prognostic biomarker and uses AI-driven frameworks for therapeutic agent discovery.

Use Cases

• Train predictive models for chemotherapy resistance risk stratification based on identified DEGs.
• Analyze the molecular and immune characteristics of the biomarker ANXA1 at bulk and single-cell levels.
• Perform AI-driven molecular docking for therapeutic agent discovery, as demonstrated with BRD-K10482608.
• Validate biomarker prognostic performance across independent patient cohorts like GSE65858.

Strengths

• Integrates data from multiple authoritative genomic sources: TCGA-HNSCC and GEO datasets.
• Applies multiple analytical frameworks: Limma, WGCNA, LASSO-Cox regression, and AI-driven RefLector.
• Validates findings in an independent cohort (GSE65858) and includes in vitro study components.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data file is a 2.9 MB DOCX, which may contain processed results rather than raw data tables.

Provenance

Source

figshare, authored by Ling Zheng.

Collection Method

Computational analysis of publicly available genomic data from TCGA and GEO databases.

Time Range

null

Freshness

Last updated 2026-03-18 07:44:40; freshness should be verified.

Geography

null